A Randomised, Placebo-Controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Trial Profile

A Randomised, Placebo-Controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Romosozumab (Primary) ; Alendronic acid; Denosumab; Teriparatide; Zoledronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 04 Apr 2017 Results of transitioning to zoledronic acid following romosozumab presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results of retreatment of a group of patients who initially randomised to romosozumab 210 mg (n=35) presented at The 99th Annual Meeting of the Endocrine Society
    • 01 Apr 2017 Updated fourth year results published in an UCB Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top